Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) EBT: 2019-2024

Historic EBT for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$105.2 million.

  • C4 Therapeutics' EBT fell 30.41% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.0 million, marking a year-over-year decrease of 13.05%. This contributed to the annual value of -$105.2 million for FY2024, which is 19.84% up from last year.
  • Per C4 Therapeutics' latest filing, its EBT stood at -$105.2 million for FY2024, which was up 19.84% from -$131.2 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' EBT ranged from a high of -$67.0 million in FY2020 and a low of -$131.2 million during FY2023.
  • Its 3-year average for EBT is -$121.5 million, with a median of -$128.2 million in 2022.
  • As far as peak fluctuations go, C4 Therapeutics' EBT crashed by 101.11% in 2020, and later increased by 19.84% in 2024.
  • Yearly analysis of 5 years shows C4 Therapeutics' EBT stood at -$67.0 million in 2020, then decreased by 25.28% to -$83.9 million in 2021, then tumbled by 52.79% to -$128.2 million in 2022, then decreased by 2.37% to -$131.2 million in 2023, then climbed by 19.84% to -$105.2 million in 2024.